1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc.

CYTHW
Cyclo Therapeutics, Inc.US flagNASDAQ Capital Market
0.03
USD
- -
- -
899,367.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
1
1
2
2
1
2
1
1
1
1
2
1
1
1
Operating Margin (%)
-7.2
16.69
25.4
-35.87
-238.35
-222.38
-310.29
-420.64
-733.8
-991.85
-899.77
-1,134.76
-1,862.69
-2,834.06
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
-1
-3
-4
-4
-4
-8
-9
-14
-15
-20
-25
Effective Tax Rate (%)
- -
25.2
28.08
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-9.47
7.1
12.1
-37.81
-268.44
-281.04
-309.68
-420.68
-747.87
-989.8
-900.94
-1,123.08
-1,863.36
-2,848.16
Working Capital
- -
- -
- -
2
2
1
1
1
1
10
16
1
4
-15
LT Debt
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1
2
2
4
4
2
1
1
1
10
16
1
5
-13
Return on Invested Capital (%)
- -
5.44
11.94
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-8.26
-18.58
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
1
3
12
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
7
4
3
Cash, Cash Equivalents & STI
3
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
10
19
Payables & Accruals
5
6
6
ST Debt
1
3
12
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
154.49%
302.65%
547.61%
Free Cash Flow
14.78%
43.89%
6.99%
Net Income, GAAP
20.2%
38.7%
29.81%
Sales/Revenue/Turnover
0.52%
5.96%
-21.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
1
- -
- -
1
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
N. Scott Fine
Full Time Employees
8
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
6714 NW 16th Street Gainesville FL United States of America
IPO Date
Dec 18, 2020
CIK
0000922247
Website
cyclotherapeutics.com
Similar Companies
Cannabis Bioscience International Holdings, Inc. (CBIH)
Beleave Inc. (BLEVF)
Ecofibre Limited (EOFBY)
ViaDerma, Inc. (VDRM)
Legacy Technology Holdings, Inc. (LTHO)
Evotec SE (0IRF.IL)
Business
Cyclo Therapeutics, Inc. (CYTHW) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of neurodegenerative diseases; its lead candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product, advances in a pivotal Phase 3 global TransportNPC trial for Niemann-Pick Disease Type C1, a rare fatal genetic disorder, with enrollment completed in May 2024 and interim analysis expected mid-2025, and in Phase IIb trials for Alzheimer's disease; the company also sells cyclodextrins and related products to pharmaceutical, nutritional, and other industries for diagnostics and specialty drugs. Incorporated in 1990 and headquartered in Gainesville, Florida, Cyclo Therapeutics operates primarily in the United States with global clinical trials and maintains an ongoing collaboration with the University of the Witwatersrand in Johannesburg to advance the Trappsol Cyclo platform and explore pipeline expansions. In March 2025, the company completed a merger with Rafael Holdings, Inc., its majority shareholder since strategic investments beginning in March 2023, which provided over $18 million in convertible debt funding since June 2024 to support operations and trial advancement; previously known as CTD Holdings, Inc., it rebranded to Cyclo Therapeutics in September 2019.